Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
1 citations
,
November 2025 in “International Journal of Dermatology” The AAcQLI is a promising tool for assessing quality of life in children with alopecia areata.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
69 citations
,
September 2013 in “American Journal of Alzheimer s Disease & Other Dementias®” Snakin-Z from jujube fruits may help treat Alzheimer's due to its enzyme inhibition and antioxidant properties.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
38 citations
,
March 1997 in “Journal of interferon & cytokine research” IL-1β inhibits human hair follicle growth.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
14 citations
,
September 2006 in “Experimental Dermatology” Interleukin‐1 α reduces androgen receptor levels and increases certain cytokines in human scalp cells.
October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
January 2023 in “Research Square (Research Square)” IGF2BP3 gene is up-regulated in keloid patients, suggesting potential targets for treatment.
June 2025 in “Medical alphabet” JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.
November 1995 in “Hair transplant forum international” The document cannot be understood or processed.
February 2026 in “Figshare” February 2026 in “Figshare”
Baricitinib may effectively treat oral lichen planus.
April 2017 in “Journal of Investigative Dermatology” Blocking JAK-STAT5 signaling in mice leads to hair growth.
105 citations
,
May 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” Activating TRPV3 stops human hair growth.
30 citations
,
August 2008 in “The journal of investigative dermatology/Journal of investigative dermatology” TGase 3 helps build hair structure by forming strong bonds between proteins.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
The PI's development is closely linked to skin and hair pigmentation in macaques.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” GATA6 is important for maintaining and differentiating cells in a key area of human skin.
4 citations
,
January 2021 in “Journal of Clinical Medical Research” c-Kit is important for heart regeneration and cancer development.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
April 2023 in “Journal of Investigative Dermatology” Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.